Assess therapeutic response by recreating the tumor itself
Our proprietary ex vivo 3D cell culture technology allows you to evaluate the specific response of a patient’s cancer to various treatment modalities and predict response before you initiate treatment.
3-Dimensional (3D) cell cultures
3D cell cultures are created from live human tumor tissue acquired through surgical biopsy or resection.
CLIA-certified laboratory
Cells are cultured under clinically and analytically validated conditions in our CLIA-certified laboratory.
Create up to 1,000 microtumors
Our cell culture platform can consistently and reliably create up to 1,000 patient-specific microtumors to test potential drug candidates.
Functional precision oncology in practice
After biopsy or primary resection, fresh, biologically active tumor tissue is immersed and transported in Kiyatec media.
Tissue is transported via UPS Healthcare™ Shipping to Kiyatec overnight using a Kiyatec-provided shipping kit.
Tissue is processed immediately upon receipt; up to 1,000 microtumors are created and treated with cancer drugs.
A patient-specific report is delivered to the oncologist via a HIPAA-compliant portal in a clinically actionable 7-10 days.
Ours is the leading ex vivo 3D cell culture platform with published, peer-reviewed evidence correlating prospective therapeutic response prediction results to actual patient outcomes.
We continue to expand our horizons
Our pipeline is actively evolving to bring the promise of 3D Predict to a broader spectrum of cancer patients.
Note: Clinical trials, including their design, endpoints, and timing, are subject to change at the Company’s discretion.
Initial results may include preliminary data interim analyses that are subject to change.
Coming soon!
3D Predict for:
Brain Mets Lung (NSCLC) | Brain Mets Breast | Ovarian | Primary Breast | Primary Lung
3D Predict for:
• Brain Mets Lung (NSCLC)
• Brain Mets Breast
• Ovarian
• Primary Breast
• Primary Lung
